| 4 | BlackRock, Inc. | 6.2M | $3.4M | +628.6% | 6.714% | 0.00% |
| 5 | Avidity Partners Management LP | 5.0M | $2.8M | 0.0% | 5.440% | 0.44% |
| 6 | FRANKLIN TEMPLETON INC | 3.8M | $2.1M | 0.0% | 4.139% | 0.00% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3.4M | $1.9M | 0.0% | 3.735% | 0.00% |
| 8 | Octagon Capital Advisors LP | 3.0M | $1.7M | -41.9% | 3.320% | 0.15% |
| 9 | Blue Owl Capital Holdings LP | 2.9M | $1.6M | -42.4% | 3.193% | 0.24% |
| 10 | TCG Crossover Management, LLC | 2.7M | $1.5M | 0.0% | 2.920% | 0.04% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 1.8M | $1.0M | +203.1% | 1.992% | 0.00% |
| 12 | STATE STREET CORP | 1.4M | $783K | +505.3% | 1.538% | 0.00% |
| 13 | MPM BioImpact LLC | 1.3M | $720K | -87.8% | 1.414% | 0.04% |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 1.0M | $577K | +469.1% | 1.133% | 0.00% |
| 15 | ADAR1 Capital Management, LLC | 751K | $416K | +113.9% | 0.817% | 0.02% |
| 16 | JANE STREET GROUP, LLC | 645K | $357K | +47.7% | 0.702% | 0.00% |
| 17 | VANGUARD PORTFOLIO MANAGEMENT LLC | 639K | $354K | — | 0.695% | 0.00% |
| 18 | NORTHERN TRUST CORP | 616K | $341K | +496.2% | 0.670% | 0.00% |
| 19 | VANGUARD FIDUCIARY TRUST CO | 434K | $240K | +27.1% | 0.472% | 0.00% |
| 20 | MARSHALL WACE, LLP | 385K | $211K | -87.0% | 0.419% | 0.00% |
| 21 | XTX Topco Ltd | 294K | $163K | — | 0.320% | 0.00% |
| 22 | Qube Research & Technologies Ltd | 257K | $142K | +2155.4% | 0.280% | 0.00% |
| 23 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 228K | $126K | — | 0.248% | 0.00% |
| 24 | Pathstone Holdings, LLC | 215K | $119K | +94.9% | 0.234% | 0.00% |
| 25 | Timothy G. Youngquist 2020 Irrevocable Trust | 198K | $110K | — | 0.216% | 0.01% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in CNTX — a direct measure of their conviction.
| 79.60% |
| 1.54 pp |
| $44M |
| 43% |
| Q4 2024 | 53 | +23% | 81.14% | +5.56 pp | $76M | 31% |
| Q3 2024 | 43 | — | 75.58% | — | $111M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
35 institutions opened new positions in CNTX during Q2 2026, while 14 fully exited. 8 added to existing positions and 35 trimmed.
CNTX institutional ownership fell by 12.44 percentage points quarter-over-quarter, with a net change of +19 holders.
The top 10 institutions account for 79.6% of all reported 13F value in CNTX, and the top 25 account for 96.2%.
Across the largest Oncology Biotech peers, institutional ownership levels are: DMRA (200.0%), FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.